{
    "2020-12-02": [
        [
            {
                "time": "2021-03-15",
                "original_text": "Lilly announces 650,000 additional doses of neutralizing antibody bamlanivimab (LY-CoV555) purchased by U.S. government to treat COVID-19",
                "features": {
                    "keywords": [
                        "Lilly",
                        "bamlanivimab",
                        "U.S. government",
                        "COVID-19",
                        "doses"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2021-03-15",
                "original_text": "‘The pandemic isn’t over’ just because we have vaccines: Dr. Craig Spencer",
                "features": {
                    "keywords": [
                        "pandemic",
                        "vaccines",
                        "Dr. Craig Spencer"
                    ],
                    "sentiment_score": -0.4,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2021-03-15",
                "original_text": "CVS pilots giving Eli Lilly's COVID-19 antibody drug at patient's home",
                "features": {
                    "keywords": [
                        "CVS",
                        "Eli Lilly",
                        "COVID-19",
                        "antibody drug",
                        "home"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            }
        ]
    ]
}